Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program
Progress of China pivotal AD trial remains on track with completion of 36-week Stage 2 expected in H2 2023
https://finance.yahoo.com/news/connect-biopharma-provides-business-clinical-123000747.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.